Skip to main content
main-content

29.08.2018 | Original Article | Ausgabe 1/2019

Comparative Clinical Pathology 1/2019

PPAR-α agonist fenofibrate potentiates antioxidative elements and improves oxidative stress of hepatic cells in streptozotocin-induced diabetic animals

Zeitschrift:
Comparative Clinical Pathology > Ausgabe 1/2019
Autoren:
Habib Yaribeygi, Mohammad Taghi Mohammadi, Alexandra E. Butler, Amirhossein Sahebkar

Abstract

Oxidative stress induced by hyperglycemia has a crucial role in hepatocellular disorders. The aim of this study was to evaluate whether fenofibrate potentiates the anti-oxidant defense system of hepatocytes and thereby prevents oxidative stress. Male Wistar rats were assigned to four groups: normal control (C), normal-treated (CF), diabetic (D), and diabetic-treated (DF) (n = 6 per group). Hyperglycemia was induced with streptozotocin (single dose of 45 mg/kg into the tail vein). Treated groups received fenofibrate for 8 weeks by intragastric gavage (80 mg/kg/day). At study completion (day 56), the rats were sacrificed and liver tissue harvested. Catalase (CAT) and superoxide dismutase (SOD) enzymes activities, malondialdehyde (MDA), nitrate, and glutathione (GLT) contents were evaluated in all experimental groups. Obtained data were analyzed via two-way ANOVA, p < 0.05 taken as significant. Hyperglycemia markedly decreased SOD and CAT enzyme activities; furthermore, oxidative stress was induced via MDA content enhancement. Fenofibrate increased both SOD and CAT enzyme activities and decreased the nitrate content and MDA production in hepatic cells, thus improving oxidative stress. Our data suggest that uncontrolled hyperglycemia overwhelms the anti-oxidant defense systems of hepatic cells and oxidative damage ensues. The PPAR-α agonist Fenofibrate prevents oxidative damage in hepatocytes by potentiating the anti-oxidant defense system and can therefore improve the redox state in hepatocellular tissue.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

Comparative Clinical Pathology 1/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie

06.04.2020 | Schwerpunkt: Unser Immunsystem – der Staat im Staate | Ausgabe 3/2020

Der Darm im Fokus des Immunsystems

Seltene Darmerkrankungen bei primären Immundefekten

06.04.2020 | Schwerpunkt: Unser Immunsystem - der Staat im Staate | Ausgabe 3/2020

Das Fettgewebe im Fokus des Immunsystems: adipositasassoziierte Inflammation

02.04.2020 | Mammakarzinom | Schwerpunkt: Unser Immunsystem - der Staat im Staate | Ausgabe 3/2020

Immuntherapien beim Mammakarzinom: Neue Strategien

02.04.2020 | Schwerpunkt: Unser Immunsystem – der Staat im Staate | Ausgabe 3/2020

Das Komplementsystem – ein „hot topic“ nicht nur bei Nierenerkrankungen